CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Monday

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect CytomX Therapeutics to post earnings of $0.10 per share and revenue of $35.42 million for the quarter.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Stock Down 14.8 %

Shares of CytomX Therapeutics stock traded down $0.16 on Friday, hitting $0.93. The stock had a trading volume of 15,250,979 shares, compared to its average volume of 1,541,594. CytomX Therapeutics has a one year low of $0.40 and a one year high of $2.05. The stock's 50-day simple moving average is $0.66 and its two-hundred day simple moving average is $0.85. The stock has a market cap of $74.85 million, a price-to-earnings ratio of 5.46 and a beta of 1.11.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. StockNews.com assumed coverage on CytomX Therapeutics in a research report on Tuesday, April 15th. They issued a "hold" rating on the stock. Finally, Piper Sandler assumed coverage on CytomX Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $2.50 price objective on the stock. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, CytomX Therapeutics presently has an average rating of "Hold" and a consensus price target of $3.70.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.